Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to LX9851, an ...

The company's peptide-based therapeutics offer the potential for targeted ... and has potential to transform the treatment paradigm for these disease indications. An NDA filing of icotrokinra for ...

Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD studyTopline results from Phase ...

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor and is being studied in adults and adolescents 12 years of age and older with ...

Research reveals howneurogenic connection can directly trigger inflammatory processes, creating pain patterns that challenge ...

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb ... in a once daily pill could shift [the] treatment paradigm” for psoriasis. “The robust results seen to ...

Studies show that eating oranges daily, regular exercise, and certain medications can lower depression risk by up to 40%, ...

Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis. Click fo rmy PTGX update.

Topline results from Phase 3 ICONIC-ADVANCE 1&2�studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe plaque PsO ...

I Taiho Pharmaceutical Co., Ltd. (hereinafter "Taiho Pharmaceutical") and Araris Biotech AG (hereinafter "Araris"), a Swiss biotechnology ...